Biomaterial Database

The effect of intravenously administered almitrine, a peripheral chemoreceptor agonist, on patients with chronic air-flow obstruction. 1983

A C Powles, and D V Tuxen, and C B Mahood, and S O Pugsley, and E J Campbell

Almitrine, a peripheral chemoreceptor agonist, was given intravenously in a dose of 0.5 mg/kg/h for 2 h in a randomized double-blind manner with placebo, to 11 patients with severe chronic air-flow obstruction and hypoxemia (SaO2 less than 90%). There was no significant placebo effect. Maximal respiratory effect occurred at the end of the almitrine infusion with an increase in ventilation from 8.2 + 0.9 to 11.6 + 1.5 L/min (mean +/- SEM), and improvements in SaO2 from 83 +/- 3 to 90 +/- 2%, in PaO2 from 48 +/- 2 to 55 +/- 3 mmHg, and in PaCO2 from 54 + 3 to 47 +/- 4 mmHg. Venous admixture was reduced from 38 +/- 4% to 22 +/- 3%. In 4 patients, blood gas values substantially improved, but there was no change in total ventilation for ventilatory pattern. This study of acute effects showed that almitrine improved arterial PO2 and PCO2 in patients with chronic air-flow obstruction both by increasing ventilation and by improving ventilation-perfusion relationships.

UI	MeSH Term	Description	Entries
D007263	Infusions, Parenteral	The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping.	Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008173	Lung Diseases, Obstructive	Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.	Obstructive Lung Diseases,Obstructive Pulmonary Diseases,Lung Disease, Obstructive,Obstructive Lung Disease,Obstructive Pulmonary Disease,Pulmonary Disease, Obstructive,Pulmonary Diseases, Obstructive
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010879	Piperazines	Compounds that are derived from PIPERAZINE.
D010919	Placebos	Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.	Sham Treatment
D001784	Blood Gas Analysis	Measurement of oxygen and carbon dioxide in the blood.	Analysis, Blood Gas,Analyses, Blood Gas,Blood Gas Analyses,Gas Analyses, Blood,Gas Analysis, Blood
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000697	Central Nervous System Stimulants	A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.	Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central